RECRUITING

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

Description

This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone

Conditions

Glaucoma, Open-angleOcular Hypertension (OHT)Phacoemulsification Cataract Surgery
Talk to us

Related Conditions:

Glaucoma, Open-angleOcular Hypertension (OHT)Phacoemulsification Cataract Surgery

Study Overview

On this page

Study Details

Study overview

This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone

Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intracameral Implant) in Conjunction With Cataract Surgery vs. Cataract Surgery Alone

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

Condition
Glaucoma, Open-angle
Intervention / Treatment

-

Contacts and Locations

Kenosha

Glaukos Investigator Site, Kenosha, Wisconsin, United States, 53142

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye.
  • * OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery)
  • * Active corneal inflammation or edema.
  • * Retinal disorders not associated with glaucoma.

Ages Eligible for Study

45 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Glaukos Corporation,

Luis Vargas, STUDY_CHAIR, Glaukos Corporation

Study Record Dates

2026-09